Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meena Balasubramanian has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Michael J. Parker

    Sheffield Clinical Genomics Service, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom

    16 shared publications
  • Paul Arundel

    Highly Specialised Service for Severe, Complex and Atypical OI, Sheffield Children's NHS Foundation Trust, Sheffield, UK

    16 shared publications
  • Kath Smith

    15 shared publications
  • Amaka C. Offiah

    Sheffield Children’s NHS Foundation Trust

    11 shared publications
  • Helen Stewart

    Oxford Centre for Genomic Medicine, Department of Clinical Genetics, Churchill Hospital, Headington, Oxford, United Kingdom

    11 shared publications
  • Sahar Mansour

    South West Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, United Kingdom; School of Biological and Molecular Sciences, St George's University of London, London, United Kingdom

    11 shared publications

Latest Publications

  • Open Access

    Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening

    by Meena Balasubramanian

    Genomic newborn and population screening is rapidly moving from pilot to policy. England's Generation Study has already enrolled tens of thousands of babies, and NHS England has committed to offering whole-genome sequencing to every newborn within a decade. Several such international initiatives, from programmes in Massachusetts and New York to Guangdong, are rapidly expanding gene panels. This expansion, however, is associated with a growing risk of over-calling genomic variants in asymptomatic infants, for whom traditional phenotype-first diagnostic models no longer apply. Osteogenesis imperfecta (OI) provides an instructive test case. It has been long treated as a textbook example of a highly penetrant Mendelian disease; however, population-scale data now show that a substantial proportion of adults carrying ‘pathogenic’ COL1A1/COL1A2 variants have no recorded clinical diagnosis of OI. Using OI as an exemplar, this article explores what genomic screening programmes can realistically deliver, identifies other conditions sharing this penetrance gap, and outlines how programmes can expand without eroding public trust.

  • Open Access

    Using Interpretative Phenomenological Analysis to Explore the Experiences of Mothers Who Have a Child With the Rare Genetic Disorder, HNRNPU ‐Related Neurodevelopmental Disorder: “Some Days, I Wear a Cape and I'm Super Mom and Some Days, I Have to Hide Under My Cape and I Can't Get Out for a Few Days”

    by I. Overton, F. Docherty, M. Balasubramanian

    HNRNPU‐related neurodevelopmental disorder is an ultra‐rare genetic condition characterised by developmental delay, intellectual disability, seizures and a range of complex health needs. Yet, little is known about how families experience and navigate life with this diagnosis. This study explored the lived experiences of seven mothers caring for a child with HNRNPU‐NDD, using Interpretive Phenomenological Analysis of semi‐structured interviews to gain an in‐depth understanding of how they manage with daily life and sustain their well‐being. Three group experiential themes (GETs) were generated: (1) From nurturer to care manager: how hypervigilance shapes daily life and maternal identity, (2) How mothers make sense of futures that no longer look as expected: grief, fear of future and reconstruction of hope, (3) Social worlds that ‘no longer fit’: experiences of isolation and disconnection. Together, these themes show the emotional duality, identity shifts and social challenges involved in raising a child with HNRNPU‐NDD. They are discussed alongside existing literature on rare disease caregiving, highlighting shared challenges as well as aspects that appear distinctive to ultra‐rare neurodevelopmental conditions. The findings illustrate that mothers require meaningful support acknowledging the emotional weight and relational shifts of caregiving, beyond the child's symptoms. This study aims to shed light into an under‐researched condition and offer suggestions for future research which should include broader family perspectives (fathers and siblings) and the development of support systems tailored to the complex needs of this population.

  • Open Access

    Challenges in Gene‐Directed Therapies for Rare Neurodevelopmental Disorders Using HNRNPU as an Exemplar

    by Daniel Aiyedun, Susan F. Rogers, Doaa M. Taha, Meena Balasubramanian

    Next‐generation sequencing has radically transformed the diagnostic capability of rare neurodevelopmental disorders (RNDDs), yet translating these molecular insights into viable therapeutics remains a hurdle. While gene‐directed modalities, specifically viral‐mediated supplementation, antisense oligonucleotides (ASOs), and CRISPR‐based activation or precision editing, offer a means to rescue loss‐of‐function phenotypes, successful clinical implementation requires moving past the reductive framework of merely increasing the expression of the target gene towards approaches that account for spatial, developmental, and therapeutic windows. This review uses HNRNPU‐related rare neurodevelopmental disorder (HNRNPU‐RNDD), a condition marked with global developmental delay and refractory epilepsy, as an exemplar to discuss these translational hurdles. We discuss the homeostatic boundaries of this scaffold attachment factor, where unregulated overexpression risks localised cytotoxicity, and altered chromatin dynamics compromise editing safety. Furthermore, we assess how cell‐type sensitivity and narrow developmental windows may dictate clinical efficacy. By using HNRNPU‐RNDD to critically analyse the challenges of using each therapeutic platform, we hope to inform the creation of gene‐directed therapies that aim to treat disorders resulting from structural pleiotropic dosage‐sensitive proteins.

  • Evolving roles within the genomic medicine workforce: a revised framework for UK practice—position on behalf of the Association of Genetic Nurses and Counsellors and the Clinical Genetics Society

    by Roberta Rizzo, Meena Balasubramanian, Diana Baralle, Catriona Corsie, Catherine Houghton, Bethany Lumborg, Emma Tonkin, Mohnish Suri

    This document is written on behalf of the two professional bodies in the UK that represent genetic counsellors (the Association of Genetic Nurses and Counsellors (AGNC)) and clinical geneticists (the Clinical Genetics Society). The delivery of genomic medicine in the UK continues to evolve in response to technological advancements, increasing demand and national strategic priorities. This paper presents an updated framework describing the professional roles within specialist genomic services, refining responsibilities across key domains of clinical care, education, research and mainstreaming. Building on previous role descriptors, through focused workshops with specific expertise, we integrated national consultation, emerging service models and policy alignment. A new colour-coded matrix delineates role-specific scope of practice for different roles as described in the AGNC career structure. A key development is the formal inclusion of the genomic practitioner role, reflecting workforce diversification. Expanded emphasis is placed on mainstreaming genomic services and involvement in clinical and psychosocial research. This updated framework provides a structured and transparent tool for workforce planning, interprofessional collaboration and service development across genomic medicine. The framework remains aspirational and adaptable, acknowledging regional variability and anticipating future service developments.

  • Open Access

    Patient-specific zebrafish models reveal a complex phenotypic spectrum in NBAS-associated Atypical Osteogenesis Imperfecta

    by Daniel A Baird, Sookyung Seo, Zuzanna Matelowska, Karthick Navin Mohandass, Alagumeenal Subramanian Annamalai, Aynour Abouelkhair, Myar Zafar, Nurhaziqah Supari, Sarah Baxendale, Catherine A Loynes, et al.

    Neuroblastoma amplified sequence gene (NBAS) variants are associated with short stature, optic atrophy, and Pelger-Huet anomaly (SOPH) syndrome. We previously identified compound heterozygous variants in NBAS to cause atypical Osteogenesis Imperfecta (OI), with these patients presenting with short stature, developmental delay and recurrent long-bone fractures. However, skeletal disease progression due to these variants and the disease mechanisms underlying NBAS-associated OI remain poorly understood. Here, we provide a clinical update on previously identified patients and investigate the role of NBAS during skeletal development using zebrafish knockout and patient-specific missense variant zebrafish models. Homozygous knockout larvae exhibited delayed operculum development, reduced bone ossification, and defects in Meckels cartilage morphology and its underlying cellular structure. Homozygous missense larvae displayed milder cartilage defects without any major defects to early skeletal structures. Seemingly opposing phenotypes were observed in compound heterozygous zebrafish carrying the knockout and missense alleles in trans, with no obvious phenotypes seen in the Meckels cartilage and accelerated operculum development observed. Together, our results demonstrate that different nbas variants differentially affect skeletal development, suggesting complex spectrums of phenotypic and pathogenic mechanisms in NBAS-associated atypical OI.

  • Complexity of genomic diagnosis: Lessons learnt from the UK Biobank and Generation study newborn genome sequencing analyses

    by Chidambaram Sethuraman, Sylvia Keigwin, Sophie Delaney, Seiko Makino, Joshua Hirst, Duncan Baker, Paul Arundel, Raja Padidela, Justin H. Davies, Belinda Crowe, et al.


  • Open Access

    Functional surrogacy enables Vascular Ehlers-Danlos Syndrome modelling in zebrafish in the absence of a COL3A1 ortholog

    by Daniel A. Baird, Nataliya Pidlisnyuk, Anna Matischen, Zuzanna Matelowska, Sookyung Seo, Nurhaziqah Supari, Jessica Bowen, Glenda Sobey, Meena Balasubramanian

    Pathogenic variants in COL3A1 cause Vascular Ehlers-Danlos syndrome (vEDS), a rare connective tissue disorder characterised by vascular fragility, increasing the risk of arterial ruptures/dissection. Advances in genomic sequencing have led to an increasing number of COL3A1 variants where the clinical significance is unclear, with these being termed ‘variants of uncertain significance’ (VUS). VUS creates challenges for diagnosis and clinical management. Thus major efforts have been made to reclassify these to either pathogenic or benign variants in disease causality. Functional data from model systems can provide significant evidence to clinicians on the pathogenicity of a variant. To address the increasing numbers of VUS in COL3A1 , we developed a fast pipeline using F0 crispant zebrafish to provide functional evidence for variant classification despite there being no direct orthologue of COL3A1 in zebrafish. Loss of col5a1 resulted in cardiac defects, dysmorphic blood vessel structures and delayed angiogenic sprouting. Trunk haemorrhage prevalence under physical stress increased in col5a1 knockout zebrafish, recapitulating vEDS patients. Remarkably, co-injection of F0 col5a1 knockout crispants with human wildtype COL3A1 mRNA partially rescued cardiac and vascular phenotypes, indicating a level of functional conservation between zebrafish type V and human type III collagen. These findings establish a tractable in vivo platform for functional assessment of COL3A1 VUS. Phenotypic rescue with wildtype COL3A1 provides a benchmark against which the pathogenicity of variants can be evaluated, generating functional evidence for VUS reclassification. Our model provides both a valuable tool for investigating vEDS disease mechanisms and a clinically relevant platform to improve diagnoses for patients with suspected vEDS.

  • Open Access

    Broadening the Inherited ASXL3 Spectrum and Unveiling Molecular Mechanisms through Detailed Genotypic-Phenotypic Analyses

    by E. Woods, N. Holmes, C. Gooch, A.S. Denommé-Pichon, A. Vitobello, M. Vincent, E. Pavlidou, A. Ververi, V.J.M. Verhoeven, M.A. van Slegtenhorst, et al.


  • Open Access

    Author Correction: Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes

    by Rocio Rius, Alexander J. M. Blakes, Yuyang Chen, Joachim De Jonghe, François Lecoquierre, Ruebena Dawes, Benjamin Cogne, Hyung Chul Kim, Javeria R. Alvi, Florence Amblard, et al.

  • Open Access

    Reduced penetrance of COL1A1/2 pathogenic variants linked with osteogenesis imperfecta: analysis of a large population cohort

    by Alistair T. Pagnamenta, James Fasham, Robin N. Beaumont, Duncan Baker, Sylvia Keigwin, Tim Hall, Emma L. Baple, Meena Balasubramanian, Leigh Jackson, Caroline F. Wright

    Osteogenesis imperfecta (OI) is under consideration for inclusion in several genomic newborn screening initiatives, but its penetrance in clinically-unselected populations is currently unknown. It is an exemplar condition for evaluating penetrance in adult cohorts due to its relatively low mortality, variable expressivity and link to several large genes. Using genome sequencing data from ~500,000 adults in UK Biobank, we curated a set of rare pathogenic/likely pathogenic (P/LP) variants in COL1A1, COL1A2 and IFITM5 using annotations from gnomAD, ClinVar and SpliceAI. Analysis of summed read-count data from genome and exome sequencing led to exclusion of 16 mosaic variants with consistently low allelic balance of 3.4–35.9%. We identified 61 likely constitutive heterozygous P/LP variants in COL1A1 and COL1A2 (29 loss-of-function or splice variants and 32 missense) in 115 participants, with a mean age at recruitment of 55.1 years; no P/LP variants were identified in IFITM5 . Phenotypes were assessed using ICD-10 codes, self-reports and heel bone mineral density (BMD). Overall disease penetrance was lower than anticipated: 40.7% for COL1A1 and 21.3% for COL1A2 , potentially due to depletion of severe early-onset disease. When considering only truncating variants in COL1A1 , disease penetrance increased to 73.1%, and 90% of individuals had reduced levels of circulating COL1A1 protein. For COL1A2 , BMD data supported the low penetrance, whereas for COL1A1 , data suggested the possibility of a subclinical phenotype. Overall, for P/LP missense variants (including those altering Gly-Xaa-Yaa repeats), the low penetrance observed suggests reliance on current ClinVar assertions to support pathogenicity may overstate OI risk in population screening.